These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24010978)

  • 1. Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised state.
    Doan TT; Phung TT; Pham HV; Pham SH; Nguyen LT
    BMC Infect Dis; 2013 Sep; 13():424. PubMed ID: 24010978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir therapy in two immunocompetent infants with severe acquired CMV pneumonitis.
    Suresh N; Thiruvengadam V
    Paediatr Int Child Health; 2013 Feb; 33(1):46-8. PubMed ID: 23485496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice.
    Duan J; Paris W; Kibler P; Bousquet C; Liuzzi M; Cordingley MG
    Antiviral Res; 1998 Oct; 39(3):189-97. PubMed ID: 9833959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ganciclovir drug exposure in children receiving standard ganciclovir dosing.
    Yang W; Irwin A; Weerdenburg H; McWhinney B; Cole T; Lei A; Han B; Zhu X; Gwee A
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0052524. PubMed ID: 39291998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of topical application of 0.15% ganciclovir gel on cytomegalovirus corneal endotheliitis.
    Koizumi N; Miyazaki D; Inoue T; Ohtani F; Kandori-Inoue M; Inatomi T; Sotozono C; Nakagawa H; Horikiri T; Ueta M; Nakamura T; Inoue Y; Ohashi Y; Kinoshita S
    Br J Ophthalmol; 2017 Feb; 101(2):114-119. PubMed ID: 27142389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cytomegalovirus pneumonia in an immunocompetent patient: a very uncommon but treatable condition.
    Waqas QA; Abdullah HMA; Khan UI; Oliver T
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir therapy for cytomegalovirus-associated liver disease in immunocompetent or immunocompromised children.
    Nigro G; Krzysztofiak A; Bartmann U; Clerico A; Properzi E; Valia S; Castello M
    Arch Virol; 1997; 142(3):573-80. PubMed ID: 9349303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital Cytomegalovirus Pneumonitis and Treatment Response Evaluation Using Viral Load during Ganciclovir Therapy: a Case Report.
    Lee-Yoshimoto M; Goishi K; Torii Y; Ito Y; Ono H; Mori T; Kashiwa N; Hosokawa S; Shichino H
    Jpn J Infect Dis; 2018 Jul; 71(4):309-311. PubMed ID: 29709989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation.
    Park GE; Ki HK; Ko JH
    BMC Infect Dis; 2021 May; 21(1):414. PubMed ID: 33947335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Different dosages Ganciclovir treatment of symptomatic congenital cytomegalovirus infection in neonatal].
    Hong-Bin Z; Feng-Xian Z; Cai-Ping G
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Feb; 26(1):57-9. PubMed ID: 22919757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
    Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
    Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.
    Brosgart CL; Louis TA; Hillman DW; Craig CP; Alston B; Fisher E; Abrams DI; Luskin-Hawk RL; Sampson JH; Ward DJ; Thompson MA; Torres RA
    AIDS; 1998 Feb; 12(3):269-77. PubMed ID: 9517989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Kamil E
    Am J Transplant; 2002 Aug; 2(7):671-3. PubMed ID: 12201370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group.
    Frenkel LM; Capparelli EV; Dankner WM; Xu J; Smith IL; Ballow A; Culnane M; Read JS; Thompson M; Mohan KM; Shaver A; Robinson CA; Stempien MJ; Burchett SK; Melvin AJ; Borkowsky W; Petru A; Kovacs A; Yogev R; Goldsmith J; McFarland EJ; Spector SA
    J Infect Dis; 2000 Dec; 182(6):1616-24. PubMed ID: 11069232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.